Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL® Dosing Regimens
Alpha Cognition Inc. announced that the U.S. Patent and Trademark Office has issued a new patent covering specific oral dosing regimens for benzgalantamine, the active therapy in its FDA-approved Alzheimer’s treatment ZUNVEYL. The patent is expected to strengthen the company’s intellectual property protection and provide exclusivity in the U.S. through July 2045, supporting long-term differentiation and commercial value.
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL® Dosing Regimens